General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Pharmaceuticals

Innovating to treat disease more effectively

Our global Pharmaceuticals portfolio includes more than 40 key marketed products, many of which are innovative leaders in their therapeutic areas. In 2011 we received a total of 15 approvals in the United States, Europe and Japan.

Learn more about our Pharmaceuticals Division

Learn more about Novartis pharmaceuticals in your country:

Key pharmaceutical products marketed by Novartis are listed below in alphabetical order:

A C D E F G I L M N O R S T V X Z

Miacalcin/Miacalcic (salmon calcitonin)

Myfortic (mycophenolic acid/mycophenolate sodium, USP)